Paul Sorajja, MD, discusses the late-breaking TRILUMINATE pivotal trial at ACC.23 and how tricuspid TEER performed against the current standard of care using medical therapy.

ACC.23 Program Chair Doug Drachman, MD, explains what he saw as some of the key takeaways from the American College of Cardiology (ACC) 2023 annual meeting.

Researchers examined data from more than 700 TAVR patients, publishing their findings in the American Journal of Cardiology.

One key takeaway was that women faced a higher MI risk than men, but only for the first 30 days. 

As much as TAVR's popularity has grown in recent years, there are still many instances when a heart team may find that surgery offers the best path forward. 

Sahil Parikh, MD, talked to Cardiovascular Business about growing trends related to the treatment of critical lower limb ischemia. "We are getting better and better at saving their limbs, but we are not better at saving their lives," he said. 

Read our monthly recap of FDA-related news items from the world of cardiovascular medicine. 

Both vendors used the four-day conference as an opportunity to provide key updates about their TAVR valves.